Escitalopram: What Does it Have to Offer?

Steven Phillip Wengel, William J. Burke

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Where does escitalopram, the latest antidepressant, fit in the universe of selective serotonin reuptake inhibitors (SSPIs)? SSRIs, including fluoxetine, fluvoxamine, sertraline, citalopram, and paroxetine, are among the most commonly prescribed antidepressants due to their demonstrated efficacy and relatively benign side-effect profile. Citalopram is a racemic mixture of R- and S-enantiomers. The S-enantiomer, escitalopram, is the therapeutically active portion of the parent compound, whereas the R enantiomer does not contribute to clinical efficacy and may account for some of the side effects of citalopram. Escitalopram is the most serotonin-selective of the SSRIs, has relatively little effect on the cytochrome P450 system, and is less protein bound than other SSRIs. It is also well-tolerated and may offer a quicker onset of therapeutic action than citalopram in depressed patients. Like other SSRIs, it is also effective in relieving anxiety symptoms associated with depression.

Original languageEnglish (US)
Pages (from-to)67-70
Number of pages4
JournalPrimary Psychiatry
Volume10
Issue number1
StatePublished - Jan 1 2003

Fingerprint

Citalopram
Antidepressive Agents
Fluvoxamine
Sertraline
Paroxetine
Fluoxetine
Serotonin Uptake Inhibitors
Cytochrome P-450 Enzyme System
Serotonin
Anxiety
Depression

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Escitalopram : What Does it Have to Offer? / Wengel, Steven Phillip; Burke, William J.

In: Primary Psychiatry, Vol. 10, No. 1, 01.01.2003, p. 67-70.

Research output: Contribution to journalReview article

Wengel, SP & Burke, WJ 2003, 'Escitalopram: What Does it Have to Offer?', Primary Psychiatry, vol. 10, no. 1, pp. 67-70.
Wengel, Steven Phillip ; Burke, William J. / Escitalopram : What Does it Have to Offer?. In: Primary Psychiatry. 2003 ; Vol. 10, No. 1. pp. 67-70.
@article{d4e8d64bd21a497c8b2096ede82977d4,
title = "Escitalopram: What Does it Have to Offer?",
abstract = "Where does escitalopram, the latest antidepressant, fit in the universe of selective serotonin reuptake inhibitors (SSPIs)? SSRIs, including fluoxetine, fluvoxamine, sertraline, citalopram, and paroxetine, are among the most commonly prescribed antidepressants due to their demonstrated efficacy and relatively benign side-effect profile. Citalopram is a racemic mixture of R- and S-enantiomers. The S-enantiomer, escitalopram, is the therapeutically active portion of the parent compound, whereas the R enantiomer does not contribute to clinical efficacy and may account for some of the side effects of citalopram. Escitalopram is the most serotonin-selective of the SSRIs, has relatively little effect on the cytochrome P450 system, and is less protein bound than other SSRIs. It is also well-tolerated and may offer a quicker onset of therapeutic action than citalopram in depressed patients. Like other SSRIs, it is also effective in relieving anxiety symptoms associated with depression.",
author = "Wengel, {Steven Phillip} and Burke, {William J.}",
year = "2003",
month = "1",
day = "1",
language = "English (US)",
volume = "10",
pages = "67--70",
journal = "Primary Psychiatry",
issn = "1082-6319",
publisher = "MBL Communications",
number = "1",

}

TY - JOUR

T1 - Escitalopram

T2 - What Does it Have to Offer?

AU - Wengel, Steven Phillip

AU - Burke, William J.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Where does escitalopram, the latest antidepressant, fit in the universe of selective serotonin reuptake inhibitors (SSPIs)? SSRIs, including fluoxetine, fluvoxamine, sertraline, citalopram, and paroxetine, are among the most commonly prescribed antidepressants due to their demonstrated efficacy and relatively benign side-effect profile. Citalopram is a racemic mixture of R- and S-enantiomers. The S-enantiomer, escitalopram, is the therapeutically active portion of the parent compound, whereas the R enantiomer does not contribute to clinical efficacy and may account for some of the side effects of citalopram. Escitalopram is the most serotonin-selective of the SSRIs, has relatively little effect on the cytochrome P450 system, and is less protein bound than other SSRIs. It is also well-tolerated and may offer a quicker onset of therapeutic action than citalopram in depressed patients. Like other SSRIs, it is also effective in relieving anxiety symptoms associated with depression.

AB - Where does escitalopram, the latest antidepressant, fit in the universe of selective serotonin reuptake inhibitors (SSPIs)? SSRIs, including fluoxetine, fluvoxamine, sertraline, citalopram, and paroxetine, are among the most commonly prescribed antidepressants due to their demonstrated efficacy and relatively benign side-effect profile. Citalopram is a racemic mixture of R- and S-enantiomers. The S-enantiomer, escitalopram, is the therapeutically active portion of the parent compound, whereas the R enantiomer does not contribute to clinical efficacy and may account for some of the side effects of citalopram. Escitalopram is the most serotonin-selective of the SSRIs, has relatively little effect on the cytochrome P450 system, and is less protein bound than other SSRIs. It is also well-tolerated and may offer a quicker onset of therapeutic action than citalopram in depressed patients. Like other SSRIs, it is also effective in relieving anxiety symptoms associated with depression.

UR - http://www.scopus.com/inward/record.url?scp=1842452826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842452826&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:1842452826

VL - 10

SP - 67

EP - 70

JO - Primary Psychiatry

JF - Primary Psychiatry

SN - 1082-6319

IS - 1

ER -